Talphera Announces $26M Capital Commitment Through A Combination Of A Non-Dilutive Royalty Monetization And Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025$16 million of total equity committed with $6